Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Protease Cargo in Circulating Exosomes of Breast Cancer and Ovarian Cancer Patients

Tamkovich SN, Yunusova NV, Tugutova E, Somov AK, Proskura KV, Kolomiets LA, Stakheeva MN, Grigor’eva AE, Laktionov PP, Kondakova IV.

Asian Pac J Cancer Prev. 2019 Jan 25;20(1):255-262.

2.

Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.

Tsang JYS, Lee MA, Chan TH, Li J, Ni YB, Shao Y, Chan SK, Cheungc SY, Lau KF, Tse GMK.

EBioMedicine. 2018 Dec;38:89-99. doi: 10.1016/j.ebiom.2018.11.012. Epub 2018 Nov 20.

3.

LncRNA SNHG1 promoted HGC-27 cell growth and migration via the miR-140/ADAM10 axis.

Guo W, Huang J, Lei P, Guo L, Li X.

Int J Biol Macromol. 2019 Feb 1;122:817-823. doi: 10.1016/j.ijbiomac.2018.10.214. Epub 2018 Nov 1.

PMID:
30391432
4.

Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.

Pham DH, Kim JS, Kim SK, Shin DJ, Uong NT, Hyun H, Yoon MS, Kang SJ, Ryu YJ, Cho JS, Yoon JH, Lee JS, Cho D, Lee SH, Park MH.

Anticancer Res. 2017 Oct;37(10):5507-5513.

PMID:
28982863
5.

Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.

Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN.

J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.

6.

Diallyl trisulfide, a chemopreventive agent from Allium vegetables, inhibits alpha-secretases in breast cancer cells.

Kiesel VA, Stan SD.

Biochem Biophys Res Commun. 2017 Mar 18;484(4):833-838. doi: 10.1016/j.bbrc.2017.01.184. Epub 2017 Feb 2.

PMID:
28161636
7.

Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.

Miller MA, Sullivan RJ, Lauffenburger DA.

Clin Cancer Res. 2017 Feb 1;23(3):623-629. doi: 10.1158/1078-0432.CCR-16-0869. Epub 2016 Nov 28. Review.

8.

ADAM9 silencing inhibits breast tumor cells transmigration through blood and lymphatic endothelial cells.

Micocci KC, Moritz MN, Lino RL, Fernandes LR, Lima AG, Figueiredo CC, Morandi V, Selistre-de-Araujo HS.

Biochimie. 2016 Sep-Oct;128-129:174-82. doi: 10.1016/j.biochi.2016.08.006. Epub 2016 Aug 20.

PMID:
27554339
9.

Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells.

Aydemir EA, Şimşek E, Korcum AF, Fişkin K.

Mol Med Rep. 2016 Sep;14(3):2343-51. doi: 10.3892/mmr.2016.5463. Epub 2016 Jul 1.

PMID:
27430992
10.

MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma.

Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin X, Cheng Y.

J Exp Clin Cancer Res. 2016 Jun 4;35(1):89. doi: 10.1186/s13046-016-0368-1.

11.

PITPNC1 Recruits RAB1B to the Golgi Network to Drive Malignant Secretion.

Halberg N, Sengelaub CA, Navrazhina K, Molina H, Uryu K, Tavazoie SF.

Cancer Cell. 2016 Mar 14;29(3):339-353. doi: 10.1016/j.ccell.2016.02.013.

12.

ADAM10: a new player in breast cancer progression?

Mullooly M, McGowan PM, Kennedy SA, Madden SF, Crown J, O' Donovan N, Duffy MJ.

Br J Cancer. 2015 Sep 15;113(6):945-51. doi: 10.1038/bjc.2015.288. Epub 2015 Aug 18.

13.

ADAM10 and ADAM17: New players in trastuzumab tesistance.

Duffy MJ, Crown J, Mullooly M.

Oncotarget. 2014 Nov 30;5(22):10963-4. No abstract available.

14.

Thalidomide combined with irradiation alters the activity of two proteases.

Şimşek E, Aydemir E, Korcum AF, Fişkın K.

Mol Med Rep. 2015 Feb;11(2):1535-41. doi: 10.3892/mmr.2014.2831. Epub 2014 Oct 31.

PMID:
25370353
15.

The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer.

Ergün S, Ulasli M, Igci YZ, Igci M, Kırkbes S, Borazan E, Balik A, Yumrutaş Ö, Camci C, Cakmak EA, Arslan A, Oztuzcu S.

Mol Biol Rep. 2015 Feb;42(2):497-505. doi: 10.1007/s11033-014-3793-2. Epub 2014 Oct 16.

PMID:
25318895
16.

Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.

Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, Shao YW, Aiken A, Waterhouse PD, Karamboulas C, Hess FM, Ohtsuka T, Okada Y, Ailles L, Ludwig A, Wrana JL, Kislinger T, Khokha R.

Nat Cell Biol. 2014 Sep;16(9):889-901. doi: 10.1038/ncb3021. Epub 2014 Aug 24.

PMID:
25150980
17.

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.

Oncotarget. 2014 Aug 30;5(16):6633-46.

18.

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, Kabelitz D.

Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18.

19.

TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.

Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, Brünner N, Schrohl AS.

Tumour Biol. 2013 Apr;34(2):1161-70. doi: 10.1007/s13277-013-0659-5. Epub 2013 Jan 22.

PMID:
23334956
20.

Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal.

Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST, Majumder S.

J Biol Chem. 2011 Dec 9;286(49):42292-302. doi: 10.1074/jbc.M111.270926. Epub 2011 Oct 18. Retraction in: J Biol Chem. 2018 Mar 9;293(10 ):3588.

Supplemental Content

Loading ...
Support Center